文献库搜索 | GeneLibs

Lynce(F),Graham(N),Kochupurakkal(BS),Nguye... Clin Cancer Res 2026-02-04

...BRCA2) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 5...

Yamada(A),Oshi(M),Isa(T),Koyasu(T),Takatsu... Jpn J Clin Oncol 2026-03-13

...BRCA2 (31 individuals). The most common cancer was breast cancer (74.6%), followed by ovarian (13.6%), and pancreatic ca...

Ikegami(M),Zhang(L),Hirata(M),Yamaguchi(T)... Clin Cancer Res 2026-02-17

...BRCA2 (13%-16% in ovarian/peritoneal cancers), and NF1 (16% in peripheral nerve tumors). Genes with >50% GCR included RA...

Rugo(HS),Cescon(DW),Robson(ME),Im(SA),Dale... Clin Cancer Res 2026-03-02

...BRCA2 mutations (tBRCAm), HRs for PFS (HR, 0.70; 95% CI, 0.33-1.48) and OS (0.81; 95% CI, 0.28-2.37) favored pembrolizum...

Chang(TY),Chien(YW),Chen(SH),Sokolow(A),Wa... Cancer Res 2026-04-02

...BRCA2), leading to a double "two-hit" involving TP53 and BRCA1/2. Tumor invasion was associated with the activation of i...

Moghadasi(S),Zanti(M),Bleeker(F),Blok(M),B... J Med Genet 2026-02-20

The BRCA2 c.8351G>A p.(Arg2784Gln) variant has long been classified as a variant of uncertain significance (VUS) due to ...

Sasagawa(H),Narita(S),Matsuda(K),Kosaka(T)... JNCI Cancer Spectr 2026-01-09

...BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanal...

Sassi(L),Martinez Marroquin(A),Waked(S),Ar... EMBO J 2026-02-00

...BRCA2, and other HR factors at the core of a broader genome-maintenance network that operates by a "prevent and protect"...

Peng(X),Song(R),Fan(Y),Wang(J),Li(Q),Mo(H)... Ther Adv Med Oncol None

...BRCA2 (N = 30), gBRCA (N = 4), somatic BRCA2 (sBRCA2; N = 1), gPALB2 (N = 4), and other HRR gene (N = 4) PVs carriers we...

Bonamici(L),Artuso(L),Marino(M),Toss(A),Si... Hum Mutat None

...BRCA2 remains underexplored. This observational study analyzed data from 2949 patients, primarily affected by breast or ...